← Back to Screener
Immunic, Inc. Common Stock (IMUX)
Price$15.13
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)101.51%
Price vs S&P 500 (4W)50.05%
VGM Score88.26
Market Capitalization$203.78M
All Metrics
Book Value / Share (Quarterly)$11.10
P/TBV (Annual)0.43x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.98
Price vs S&P 500 (YTD)169.22%
EPS (TTM)$-5.42
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-5.42
EPS (Annual)$-6.24
ROI (Annual)-545.37%
Cash / Share (Quarterly)$13.70
ROA (Last FY)-404.01%
EBITD / Share (TTM)$-5.33
ROE (5Y Avg)-215.14%
Cash Flow / Share (Annual)$-7.14
P/B Ratio1.35x
P/B Ratio (Quarterly)0.96x
Net Income / Employee (Annual)$-1,056,200
Net Interest Coverage (TTM)-15.34x
ROA (TTM)-132.04%
EPS Incl Extra (Annual)$-6.24
Current Ratio (Annual)0.75x
Quick Ratio (Quarterly)4.90x
3-Month Avg Trading Volume0.35M
52-Week Price Return120.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
52-Week High$15.77
EPS Excl Extra (Annual)$-6.24
CapEx CAGR (5Y)1.43%
Tangible BV CAGR (5Y)17.83%
26-Week Price Return117.44%
Quick Ratio (Annual)0.56x
13-Week Price Return57.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.92x
Enterprise Value$17.15M
Book Value / Share Growth (5Y)-17.83%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.29
3-Month Return Std Dev96.44%
Net Income / Employee (TTM)$-1,133,600
ROE (Last FY)-545.37%
EPS Basic Excl Extra (Annual)$-6.24
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.42
ROI (TTM)-130.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.89
Price vs S&P 500 (52W)91.79%
Year-to-Date Return180.15%
5-Day Price Return14.64%
EPS Normalized (Annual)$-6.24
ROA (5Y Avg)-196.68%
Month-to-Date Return55.51%
Cash Flow / Share (TTM)$-3.00
EBITD / Share (Annual)$-6.62
ROI (5Y Avg)-215.14%
EPS Basic Excl Extra (TTM)$-5.42
P/TBV (Quarterly)1.01x
P/B Ratio (Annual)4.89x
Book Value / Share (Annual)$2.04
Price vs S&P 500 (13W)48.06%
Beta1.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-130.32%
52-Week Low$5.06
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-1.08est. -0.93
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.27
4.27
4.33
4.36
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMUXImmunic, Inc. Common Stock | — | — | A | $15.13 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Immunic is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company's pipeline includes three lead candidates: IMU-838 (immune cell metabolism inhibitor), IMU-935 (RORγt pathway modulator), and IMU-856 (intestinal barrier restoration). These therapies target large patient populations with significant unmet treatment needs.